KALY PPS Breaks Out with Record Volume on Cannabis News Heading To 300% Potential Gain
October 22 2018 - 10:10AM
InvestorsHub NewsWire
KALY PPS Breaks Out with Record
Volume on Cannabis News Heading To 300% Potential Gain
New York, NY -- October 22,
2018 -- InvestorsHub NewsWire -- nextbigticker.com
-- Kali, Inc. (USOTC:
KALY) trading reached record high volume on Friday with over
600 million shares traded. The price per share (PPS) jumped
up 100% to close at $0.0006. With a 52-week high of $0.0021,
the PPS could still climb over another 300% back to its 52 week
high now that the company has entered the red hot cannabis
sector.
Kali, Inc. (USOTC:
KALY) announced a letter of intent (LOI) on Friday, October
19th, 2018 to acquire NCM Biotech. The Friday
press release reported that NCM Biotech has
developed a patented cannabis extraction process - U.S. Patent No.
9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS
PLANT MATERIALS INCLUDING THE CANNABIS PLANT.” NCM’s process
has been engaged in a number of medical and pharmaceutical research
and development projects in addition to being licensed to Puration,
Inc. (USOTC:
PURA) for commercial applications.
“I have received doctor feedback
from more than one of our research initiatives that extracts coming
from NCM Biotech’s patented process are superior in purity and
quality to any other available cannabis extracts,” said Frederick
Ferri, CEO and Founder of NCM Biotech. “Some feedback has
specifically indicated that a number of our candidate
pharmaceutical products under development have a greater efficacy
potential than GW Pharmaceutical [GWPRF] products
and candidate products.
The acquisition plans contemplate
NCM management assuming the senior management positions at Kali in
conjunction with the planned acquisition.
NCM
Biotech’s medical advisory team includes John N.
Gaitanis, MD., Director of Child Neurology at Tufts Medical
Center/Floating Hospital for Children; Lloyd R. Saberski,
M.D., Associate Professor of Anesthesiology and Chronic Pain
Management, Yale University, and John McMichael, Ph.D., President
& CEO Beech Tree Labs.
Kali plans to pursue pharmaceutical
and other commercial applications of its patented extraction
process building on the success of its current research projects
and its success with Puration.
Kali maintains assets and operations
today in the marina management business of which it plans to divest
in conjunction with the planned acquisition of NCM
Biotech.
Learn more about NCM Biotech at
https://www.ncmbiotech.com/
Disclaimer/Safe
Harbor:
This news release contains
forward-looking statements within the meaning of the Securities
Litigation Reform Act. The statements reflect the Company's current
views with respect to future events that involve risks and
uncertainties. Among others, these risks include the expectation
that any of the companies mentioned herein will achieve significant
sales, the failure to meet schedule or performance requirements of
the companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not
occur.
Source: www.nextbigticker.com
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024